Exone end to end binder jetting service

Organovo Pre-Announces Quarterly & Annual Financial Data to the Market’s Delight

Metal Parts Produced
Commercial Space
Medical Devices

Share this Article

o1If you hold shares of Organovo stock (NYSE MKT: ONVO), then you know that the past 18 months have been a rollercoaster ride. Shares of the stock have bounced between $12.50 in late 2013, to as low as $3.66 just last month. Certainly investors can’t be happy with the recent share price movement. With that said, the company themselves continues to make tremendous progress within the 3D printed human tissue space.

With investors up in arms as of late, and a share price which company executives likely see us underpriced, Orgonovo today did something that’s somewhat rare, they pre-announced preliminary 2015 fourth quarter and year end financial information.

“We are pleased to report preliminary fourth quarter and annual results which primarily reflect the initial uptake of our pre-launch product and services,” said Chief Financial Officer o4Barry Michaels. “Fiscal 2015 was an exceptional year of accomplishment for Organovo, as we locked down our liver toxicity product and initiated commercial launch of our product and service in November. We expect to gain greater adoption from the global pharmaceutical community and look forward to partnering with them in the discovery and development of their products. Moreover, we are excited about our development progress with a kidney tissue product as well as the opportunity to expand our footprint to include applications within the cosmetics industry. We enter fiscal 2016 with confidence and momentum and look forward to continued expansion of our platform technology across multiple industries utilizing various fully cellular tissues.”

Below you will find the numbers that the company released today, all which are unaudited:

  • Total estimated revenue for the quarter which ended March 31, 2015 are approximately $268,000, while earnings for the entire fiscal year are around $571,000.
  • Net cash utilization for the quarter is estimated at around $6.3 million and annual cash utilization for the fiscal year is estimated at around $21.1 million
  • Organovo closed the fiscal year out with $50.1 million in cash and cash equivalents on their balance sheet.o3

One of the main causes of the recent price decline, likely stems from fear by investors that the company will eventually run out of cash and require a secondary offering. While this is certainly a possibility, the fact that revenues are now picking up, and there are still over 2 years of cash and cash equivalents remaining on the balance sheet at the current burn rate, perhaps today’s preliminary report is the fuel the stock has needed to bounce back.

The company seems to have their hands in many verticals within the bioprinting space, and it will likely be another year before any major revenue is realized, but the long term dynamics of Organovo seem strong, and if managed correctly they very well could become a giant within the industry.

Are you a shareholder of Organovo? Let’s hear your thoughts on today’s report. Discuss in the Organovo forum thread on 3DPB.com. For full disclosure, I am a shareholder in this company and have been for two years.

Share this Article


Recent News

Quick, Easy Post-Processing of 3D Printed Parts with Ultimaker’s PVA Removal Station

Fashion Designer Reimagines Footwear Landscape with 3D Printed HERON01 Sneaker



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Polly Polymer’s 3D Printing “Super Factory” Driven by $15.5M Investment

Polly Polymer, a startup in China that develops high-speed stereolithography (SLA) 3D printing equipment, polymers, and software, raised 100 million Chinese Yuan ($15.5 million) in a Series A+ round. The...

New adidas 4DFWD Shoes with 3D Printed Midsoles Available for Purchase

Update: The new 4DFWD shoes from adidas, just worn on the podium by adidas athletes at the Tokyo Olympics, are now available to the public for purchase for $200. adidas has...

LLNL’s 3D Printed Electrodes Could Convert CO2 to Renewable Energy

Scientists and engineers at Lawrence Livermore National Laboratory (LLNL) are now 3D printing flow-through electrodes (FTEs), which are critical components in electrochemical reactors. Electrochemical reactors can convert carbon dioxide into...

Featured

Rawlings, Carbon and Fast Radius Use 3D Printing to Revolutionize Baseball Glove Design

Since the 2021 Major League Baseball season began, New York Mets shortstop Francisco Lindor has been seen sporting Rawlings next-generation glove in stylish, eye-catching neon green and black design. Meticulously...


Shop

View our broad assortment of in house and third party products.